Published Paper Details:

The present study focuses on the development and evaluation of sustained release gastroretentive floating beads of Glipizide to enhance gastric residence time and improve oral bioavailability for effective type 2 diabetes management. Glipizide, a second-generation sulfonylurea, is characterized by a short biological half-life and site-specific absorption in the upper gastrointestinal tract, making it an ideal candidate for gastroretentive drug delivery systems. Floating beads were prepared using ionotropic gelation with a blend of polymers including Hydroxypropyl Methylcellulose (HPMC K4M), Carbopol, Eudragit RL-100, and Sodium Alginate, with calcium chloride serving as the crosslinking agent. The formulations were evaluated for drug-polymer compatibility using Fourier-transform infrared spectroscopy (FTIR), and assessed for buoyancy behavior, entrapment efficiency, particle morphology, swelling index, and in vitro drug release. Among the various formulations, the optimized batch demonstrated excellent floating capacity (more than 12 hours), high drug entrapment efficiency (>85%), and sustained release over a 10-hour period. Drug release followed non-Fickian diffusion as indicated by Higuchi and Korsmeyer-Peppas kinetic models. The study concludes that gastroretentive floating beads of Glipizide provide a promising controlled-release system that may improve glycemic control, reduce dosing frequency, and enhance patient compliance. Further in vivo studies are recommended to substantiate these in vitro findings and confirm clinical applicability.